Nationwide Fund Advisors cut its stake in Haemonetics Corporation (NYSE:HAE) by 5.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,155 shares of the medical instruments supplier’s stock after selling 2,043 shares during the period. Nationwide Fund Advisors owned 0.06% of Haemonetics worth $1,533,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. Tudor Investment Corp ET AL increased its holdings in shares of Haemonetics by 0.5% during the second quarter. Tudor Investment Corp ET AL now owns 28,126 shares of the medical instruments supplier’s stock valued at $1,111,000 after purchasing an additional 143 shares during the period. Arizona State Retirement System grew its holdings in Haemonetics by 1.1% during the second quarter. Arizona State Retirement System now owns 27,397 shares of the medical instruments supplier’s stock worth $1,082,000 after acquiring an additional 300 shares during the period. Amalgamated Bank grew its holdings in Haemonetics by 5.7% during the second quarter. Amalgamated Bank now owns 7,322 shares of the medical instruments supplier’s stock worth $289,000 after acquiring an additional 392 shares during the period. American Century Companies Inc. grew its holdings in Haemonetics by 0.9% during the second quarter. American Century Companies Inc. now owns 46,271 shares of the medical instruments supplier’s stock worth $1,827,000 after acquiring an additional 425 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in Haemonetics by 1.2% during the second quarter. The Manufacturers Life Insurance Company now owns 39,906 shares of the medical instruments supplier’s stock worth $1,575,000 after acquiring an additional 488 shares during the period.

Shares of Haemonetics Corporation (NYSE HAE) opened at $58.46 on Tuesday. The stock has a market capitalization of $3,087.75, a PE ratio of 730.84, a PEG ratio of 4.39 and a beta of 0.99. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.51 and a current ratio of 2.17. Haemonetics Corporation has a 1-year low of $36.44 and a 1-year high of $58.99.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.07. The business had revenue of $225.40 million during the quarter, compared to analyst estimates of $219.12 million. Haemonetics had a return on equity of 11.16% and a net margin of 0.50%. The firm’s revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.38 EPS. sell-side analysts anticipate that Haemonetics Corporation will post 1.7 earnings per share for the current year.

In other news, CAO Dan Goldstein sold 4,691 shares of Haemonetics stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $54.93, for a total transaction of $257,676.63. Following the completion of the sale, the chief accounting officer now directly owns 3,747 shares in the company, valued at approximately $205,822.71. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Pedro P. Granadillo sold 7,118 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $57.06, for a total value of $406,153.08. Following the completion of the transaction, the director now directly owns 31,663 shares in the company, valued at $1,806,690.78. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 47,368 shares of company stock valued at $2,602,393. 1.20% of the stock is owned by corporate insiders.

A number of research analysts recently issued reports on HAE shares. Zacks Investment Research raised Haemonetics from a “hold” rating to a “buy” rating and set a $64.00 target price on the stock in a report on Friday, November 17th. Morgan Stanley increased their price target on Haemonetics from $43.00 to $51.00 and gave the company an “equal weight” rating in a research report on Thursday, November 9th. Craig Hallum reiterated a “hold” rating and issued a $50.00 price target (up previously from $40.00) on shares of Haemonetics in a research report on Wednesday, November 8th. Finally, Barrington Research increased their price target on Haemonetics from $48.00 to $57.00 and gave the company an “outperform” rating in a research report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $53.33.

COPYRIGHT VIOLATION NOTICE: “Nationwide Fund Advisors Has $1.53 Million Holdings in Haemonetics Corporation (HAE)” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://theolympiareport.com/2017/12/26/nationwide-fund-advisors-has-1-53-million-holdings-in-haemonetics-corporation-hae.html.

Haemonetics Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.